On March, 6 WallStreet expected Acer Therapeutics Inc. (NASDAQ:ACER)’s earnings release, as reported by Faxor. This year’s earnings per share analyst estimate is expected to be $-0.45. That is 28.57 % up compareed to $-0.63 earnings per share for last year. Wall Street now sees 4.65 % negative EPS growth despite Acer Therapeutics Inc. previous quarter’s EPS of $-0.43. ACER reached $23.68 during the last trading session after $0.1 change.Currently Acer Therapeutics Inc. is uptrending after 40.37% change in last February 28, 2018. ACER has 22,655 shares volume. ACER outperformed the S&P500 by 40.37%.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs.The firm is valued at $238.06 million. The firm offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease .Last it reported negative earnings. It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD).

For more Acer Therapeutics Inc. (NASDAQ:ACER) news published recently go to: Seekingalpha.com, Seekingalpha.com, Globenewswire.com, Globenewswire.com or Nasdaq.com. The titles are as follows: “Acer files U.S. marketing application for Edsivo for connective tissue disorder – Seeking Alpha” published on October 29, 2018, “Acer Therapeutics: Multiple Aces Up Its Sleeve – Seeking Alpha” on February 11, 2019, “Acer Therapeutics to Present at the Evercore ISI HealthConX Conference – GlobeNewswire” with a publish date: November 08, 2018, “Acer Therapeutics Announces Closing of Underwritten Public Offering – GlobeNewswire” and the last “Acer Therapeutics Announces In-license of Osanetant from Sanofi – Nasdaq” with publication date: January 02, 2019.